Form 4: Vigil Neuroscience Director Acquires 12,000 Shares in Open Market Purchase

A Vigil Neuroscience director, Samantha L. Budd Haeberlein, purchased 12,000 shares of common stock at an average price of $1.71.

Summary

• Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, Inc., acquired 12,000 shares of the company's common stock on December 19, 2024.
• The shares were purchased through multiple transactions at prices ranging from $1.69 to $1.72 per share, with a weighted average price of $1.71.
• The purchase was made directly by the director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it reflects a director's purchase, which can be seen as a sign of confidence, but it's a routine transaction.

Positives

• The director's purchase indicates confidence in the company's future prospects.
• The purchase increases the director's stake in the company.

Industry Context

This is a routine Form 4 filing, which is common for publicly traded companies when insiders buy or sell shares. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• The purchase of 12,000 shares is not unusual for a director and is within the range of typical insider transactions.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Vigil Neuroscience, insider trading, stock purchase, director, common stock, share acquisition